Aryx Therapeutics I Valuation

ARYXDelisted Stock  USD 0.0005  0.00  0.00%   
Aryx Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Aryx Therapeutics from analyzing the firm fundamentals such as Number Of Shares Shorted of 89.05 K, return on asset of -0.75, and Shares Outstanding of 33.46 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
0.0005
Please note that Aryx Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Aryx Therapeutics is based on 3 months time horizon. Increasing Aryx Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aryx Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aryx Pink Sheet. However, Aryx Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  5.0E-4 Real  4.25E-4 Hype  5.0E-4 Naive  5.0E-4
The intrinsic value of Aryx Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aryx Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.0004
Real Value
0.00
Upside
Estimating the potential upside or downside of Aryx Therapeutics I helps investors to forecast how Aryx pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aryx Therapeutics more accurately as focusing exclusively on Aryx Therapeutics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00050.00050.0005
Details
Hype
Prediction
LowEstimatedHigh
0.000.00050.00
Details
Naive
Forecast
LowNext ValueHigh
0.00050.00050.0005
Details

Aryx Therapeutics Total Value Analysis

Aryx Therapeutics I is presently anticipated to have valuation of 237.58 K with market capitalization of 237.58 K, debt of 0, and cash on hands of 2.95 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aryx Therapeutics fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
237.58 K
237.58 K
0
2.95 M

Aryx Therapeutics Asset Utilization

One of the ways to look at asset utilization of Aryx is to check how much profit was generated for every dollar of assets it reports. Aryx Therapeutics I shows a negative utilization of assets of -0.75 percent, losing $0.007486 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aryx Therapeutics I shows how discouraging it operates for each dollar spent on its assets.

Aryx Therapeutics Ownership Allocation

Aryx Therapeutics holds a total of 33.46 Million outstanding shares. Almost 99.86 percent of Aryx Therapeutics outstanding shares are held by general public with 0.14 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Aryx Therapeutics Profitability Analysis

Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.

About Aryx Therapeutics Valuation

Our relative valuation model uses a comparative analysis of Aryx Therapeutics. We calculate exposure to Aryx Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aryx Therapeutics's related companies.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.

8 Steps to conduct Aryx Therapeutics' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Aryx Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Aryx Therapeutics' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Aryx Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Aryx Therapeutics' revenue streams: Identify Aryx Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Aryx Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Aryx Therapeutics' growth potential: Evaluate Aryx Therapeutics' management, business model, and growth potential.
  • Determine Aryx Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Aryx Therapeutics' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Aryx Therapeutics Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Retained Earnings-187.1 M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Aryx Pink Sheet

If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity